Instrument Inactif

Communiqués Spatializer Audio Laboratories, Inc. Other OTC

Actions

US84725L3096

Cours en clôture Other OTC
- ^USD	-

14/08	Enveric Biosciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
05/08	Enveric Biosciences publie de nouvelles données précliniques confirmant le profil non hallucinogène de son candidat principal EB-003	CI

Communiqués

14:06	Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series	BU
01/09	Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference	BU
14/08	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026	BU
05/08	Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003	BU
28/07	Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development	BU
29/06	Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit	BU
16/06	Enveric Biosciences Announces Participation in 2026 BIO International Convention	BU
09/06	Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day	BU
02/06	Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003	BU
19/05	Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003	BU
15/05	Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026	BU
13/05	Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders	BU
05/05	Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model	BU
27/04	SmallCap Emerge: ENVB, SMX, ANY, ELPW Across High-Growth Sectors	AQ
21/04	Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum	BU
18/04	Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules	BU
17/04	Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules	BU
31/03	Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates	BU
30/03	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025	AQ
27/03	Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025	BU
18/03	Enveric Biosciences Announces Registration of Five Trademarks	BU
25/02	Enveric Biosciences Announces Withdrawal of Petition Against Its Patent	BU
19/02	Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data	BU
29/01	Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option	BU
28/01	Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	BU